# Intradiscal rhGDF-6 for the Treatment of Lumbar Disc Degeneration

> **NCT07668466** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Cartago Biotech Pty Ltd** · enrollment: 60 (estimated)

## Conditions studied

- Disc Degenerative Disease
- Back Pain

## Interventions

- **BIOLOGICAL:** High Dose
- **BIOLOGICAL:** Low Dose

## Key facts

- **NCT ID:** NCT07668466
- **Lead sponsor:** Cartago Biotech Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-04
- **Primary completion:** 2028-08-31
- **Final completion:** 2030-12-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07668466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07668466, "Intradiscal rhGDF-6 for the Treatment of Lumbar Disc Degeneration". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07668466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*